Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer | Bentham Science
Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer

Author(s): R. E. Nunez-Anita, M. Cajero-Juarez and C. Aceves

Volume 11, Issue 7, 2011

Page: [775 - 786] Pages: 12

DOI: 10.2174/156800911796798931

Price: $65

Open Access Journals Promotions 2
Abstract

Peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription factors. Three subtypes -- PPAR alpha, PPAR beta, and PPAR gamma -- have been identified and are differentially expressed in tissues. Originally, they were described as molecular regulators of lipid metabolism; recently, it has been shown that they are also involved in regulating the cell cycle and apoptosis in both normal and tumoral cells. In fact, some synthetic PPAR ligands are used to treat dyslipidemia, metabolic diseases, and type 2 diabetes. Here, we review the role of PPAR gamma (PPARγ) in tumor initiation and progression, emphasizing the relationship between this isoform and the cellular and molecular mechanisms involved in the antineoplastic effect of iodine on mammary cancer.

Keywords: Antineoplastic, apoptosis, iodine, iodolactone, mammary cancer,, peroxisome proliferator-activated receptor (PPAR), sodium-iodide symporter, prostate specific antigen, thiazolinidinedione, ciglitazone, Peroxisome proliferator response element, non-steroidal anti-inflammatory drugs

Next »

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy